Report: Prostate & Breast Cancer- New Treatments & Developmental Progres TOC

1 Executive Summary

2 Methodology

3 Table of Contents

3.1 List of Boxes
3.2 List of Tables

4 Prostate Cancer

4.1.1 Introduction
4.1.2 Disease Definitions
4.1.3 Etiology & Pathophysiology
4.1.4 Epidemiology
4.1.5 Prognosis
4.2 Current Treatment Strategies
- 4.2.1 Localized Disease
  - 4.2.1.1 Locally Advanced Prostate Cancer
- 4.2.2 Metastatic Prostate Cancer
  - 4.2.2.1 Hormone-Sensitive Metastatic Prostate Cancer
  - 4.2.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer
4.3 Progress in Current Treatment Strategies
- 4.3.1 Hormone Modulators
- 4.3.2 Chemotherapy
4.4 Key Therapeutic Strategies for Future Therapies
- 4.4.1 Therapeutic Type, Targets & Mechanisms
4.5 Competitive Landscape in Drug Development: The Late Stage Pipeline
- 4.5.1 Hormone Modulators
- 4.5.2 Protein Kinase Inhibitors
- 4.5.3 Apoptotic Inducers
- 4.5.4 Immunotherapy
- 4.5.5 DNA Binding
- 4.5.6 Other
4.6 Current Drug Development: The Early Stage Pipeline
- 4.6.1 Epothilones
- 4.6.2 Protein Kinse Inhibitors
- 4.6.3 Other
- 4.6.4 Chemotherapy

5 Breast Cancer

5.1 Introduction
- 5.1.1 Disease Definitions
- 5.1.2 Etiology
- 5.1.3 Epidemiology
- 5.1.4 Prognosis
5.2 Current Treatment Strategies
- 5.2.1 Localized Disease
- 5.2.2 Advanced Disease
5.3 Progress in Current Treatment Strategies
- 5.3.1 Hormone Based Therapies
- 5.3.2 Antibodies
- 5.3.3 Chemotherapy
5.4 Key Therapeutic Strategies for Future Therapies
- 5.4.1 Therapeutic Type, Targets & Mechanisms
5.5 Competitive Landscape in Drug Development: The Late Stage Pipeline
- 5.5.1 The Epothilones
- 5.5.2 Cell Cycle & Apoptosis
- 5.5.3 Protein Kinase Inhibitors
- 5.5.4 Immunotherapy
5.6 Current Drug Development: The Early Stage Pipeline
- 5.6.1 DNA Targeting
- 5.6.2 FTIs
- 5.6.3 Antisense
- 5.6.4 New Hormone Modulators
- 5.6.5 Other
5.7 Disclaimer
- 5.7.1 Liability
- 5.7.2 Completeness

6 Drug Index

7 Company Index

List of Boxes

Box 1: The Eastern Cooperative Oncology Group Study
Box 2: Southwest Oncology Group Study 99-16 Design
Box 3: TAX 327 Study Design
Box 4: Quick Facts - Toremifene
Box 5: Quick Facts - Bevacizumab
Box 6: Quick Facts - Genasense
Box 7: Quick Facts - R-flurbiprofen
Box 8: Quick Facts - Exisulind
Box 9: Quick Facts - Provenge
Box 10: Quick Facts - GVAX
Box 11: Quick Facts - Satraplatin
Box 12: Quick Facts - Vapreotide
Box 13: Quick Facts - DCVax
Box 14: Ongoing Phase III Studies Anastrozole
Box 15: Ongoing Phase III Studies Letrozole
Box 16: Ongoing Phase III Studies Exemestane
Box 17: Ongoing Phase III Studies Goserelin
Box 18: Ongoing Phase III Studies Fulvestrant
Box 19: Ongoing Phase III Studies Trastuzumab
Box 20: Quick Facts - BMS-247550
Box 21: Quick Facts - Temsirolimus
Box 22: Quick Facts - SDX-105
Box 23: Quick Facts - 4HPR
Box 24: Quick Facts - Lapatinib
Box 25: Quick Facts - Bevacizumab
Box 26: Quick Facts - Theratope
Box 27: Erlotinib
Box 28: Gefitinib
Box 29: Imatinib
Box 30: Pemetrexed
Box 31: NX473
Box 32: Lonafarnib
Box 33: Tipifarnib
Box 34: Bortezomib
Box 35: Arzoxifene
Box 36: Patupilone
Box 37: KOS-862

List of Tables

Table 1: The TNM System
Table 2: Lifestyle factors
Table 3: Historical Summary of Clinical Studies on Patients with Late Stage Disease
Table 4: Short Facts Bicalutamide
Table 5: Short Facts Flutamide
Table 6: Short Facts Goserelin
Table 7: Short Facts Histrelin
Table 8: Short Facts Lanreotide
Table 9: Short Facts Leuprolide
Table 10: Short Facts Nilutamide
Table 11: Short Facts Abarelix
Table 12: Short Facts Mitoxantrone
Table 13: Short Facts Carboplatin
Table 14: Short Facts Docetaxel
Table 15: Short Facts Estramustine
Table 16: Summary of Recent Clinical Studies on Patients with Late Stage Disease
Table 17: Ongoing Late Stage Clinical Studies
Table 18: Cancer Immunotherapy Strategies
Table 19: Near Term Progress Toremifene
Table 20: Near Term Progress Bevacizumab
Table 21: Near Term Progress Oblimersen
Table 22: Near Term Progress R-flurbiprofen
Table 23: Near Term Progress Exisulind
Table 24: Near Term Progress APC8015
Table 25: Near Term Progress GVAX
Table 26: Near Term Progress Satraplatin
Table 27: Summary of Prostate Cancer Late Stage Pipeline
Table 28: Epothilone
Table 29: Ixabepilone
Table 30: PTK/ZK
Table 31: Imatinib
Table 32: Bortezomib
Table 33: Sorafenib
Table 34: Arsenic trioxide
Table 35: Retinoic Acid
Table 36: Paclitaxel
Table 37: Doxorubicin
Table 38: Summary of Prostate Cancer Early Stage Pipeline
Table 39: The Stage System
Table 40: Risk Factors
Table 41: List of Approved Drugs and Their Mechanisms of Action.
Table 42: Hormonal Treatment Strategies
Table 43: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer
Table 44: Treatment Options for Women With Axillary Node-Positive Breast Cancer
Table 45: Chemotherapy Drugs and Regimen
Table 46: Summay of Drugs Involved in Breast Cancer Therapy
Table 47: Short Facts Tamoxifen
Table 48: Short Facts Anastrozole
Table 49: Short Facts Letrozole
Table 50: Short Facts Exemestane
Table 51: Short Facts Goserelin
Table 52: Short Facts Fulvestrant
Table 53: Short Facts Trastuzumab
Table 54: Cancer Immunotherapy Strategies
Table 55: Progress on Ixabepilone
Table 56: Progress on CCI-779
Table 57: Progress on Fenretinide
Table 58: Progress on Lapatinib
Table 59: Progress on Bevacizumab
Table 60: Progress on Theratope
Table 61: Summary of Mid-Stage to Late stage Investigational Agents Under Development
Table 62: Summary of Breast Cancer Early Stage Pipeline